PFE - Why Is Blood Purification Focused CytoSorbents Trading Lower Today? | Benzinga
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S. and Canadian STAR-T trial.
The trial assessed DrugSorb-ATR's ability to reduce perioperative bleeding in 140 enrolled patients on AstraZeneca Plc (NASDAQ: AZN) Brilinta/Brilique (ticagrelor) undergoing cardiothoracic surgery before completing the recommended washout period.
Patients were randomized in a 1:1 ratio to receive either DrugSorb-ATR or a sham device during cardiopulmonary bypass, with a primary composite effectiveness endpoint ...